This conference will cover pre-clinical assessment criteria for AD diagnosis such as risk profiling; population group assessment; stages of AD progression; how external stimuli influence studies and outcome; emerging frontiers in biomarker development to aid more accurate diagnosis and tracking of tau-mediated neuronal death to help further drug development; as well as more answers into how AD occurs, and most importantly when.

The conference will gather leading researchers and clinical managers to discuss models, diagnostic imaging, and novel therapeutic platforms